Characteristics, treatment patterns, healthcare resource utilization, and costs in patients with eosinophilic esophagitis in the United States: a retrospective analysis of insurance claims data
Considerable disease burden is experienced by patients with EoE (before and after diagnosis), which contributes to a high level of HCRU and increased costs.
Authors
- Heide A. Stirnadel-Farrant (ORCID: https://orcid.org/0000-0003-0734-0422)
- Mirna Chehade (ORCID: https://orcid.org/0000-0002-7177-2791)
- Juliana Meyers (ORCID: https://orcid.org/0000-0003-2938-2957)
- Rohit Katial (ORCID: https://orcid.org/0000-0002-0627-2467)
- Stephanie Chen (ORCID: https://orcid.org/0009-0009-2415-1499)
- Danuta Kielar (ORCID: https://orcid.org/0009-0003-1814-1100)
- Xiao Xu (ORCID: https://orcid.org/0000-0003-1083-3834)
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (France) (FR)
- RTI Health Solutions (US)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1177/17562848251391090
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 0.00